NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · Journal of the National Comprehensive Cancer Network · 2021
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
Cited by 945 works. doi:10.6004/jnccn.2021.0013 Open-access PDF
Authors
- David S. Ettinger
- Douglas E. Wood
- Dara L. Aisner
- Wallace Akerley
- Jessica Ruth Bauman
- Ankit Bharat
- Débora S. Bruno
- Joe Yujiao Chang
- Lucian R. Chirieac
- Thomas Anthony D’Amico
- Thomas J. Dilling
- Jonathan E. Dowell
- Scott N. Gettinger
- Matthew A. Gubens
- Aparna Madhukeshwar Hegde
- Mark W. Hennon
- Rudy P. Lackner
- Michael D. Lanuti
- Ticiana A.B. Leal
- Jules Lin
References
- SEER Cancer Statistics Review, 1975-2003
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Cancer Statistics, 2021
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden